[1] |
De Bonis P, Olei S, Mongardi L, et al. Chronic subdural hematoma in patients aged 80 years and older: a two-centre study[J]. Clin Neurol Neurosurg, 2018, 170: 88-92.
|
[2] |
Chan DY, Chan DT, Sun TF, et al. The use of atorvastatin for chronic subdural haematoma: a retrospective cohort comparison study[J]. Br J Neurosurg, 2017, 31(1): 72-77.
|
[3] |
Ban SP, Hwang G, Byoun HS, et al. Middle meningeal artery embolization for chronic subdural hematoma[J]. Radiology, 2018, 286(3): 992-999.
|
[4] |
Jiang R, Zhao S, Wang R, et al. Safety and efficacy of atorvastatin for chronic subdural hematoma in Chinese patients: a randomized clinical trial[J]. JAMA Neurol, 2018, 75(11): 1338-1346.
|
[5] |
Wang S, Ma Y, Zhao X, et al. Risk factors of hospital mortality in chronic subdural hematoma: a retrospective analysis of 1117 patients, a single institute experience[J]. J Clin Neurosci, 2019, 67: 46-51.
|
[6] |
Manickam A, Marshman LA, Johnston R. Long-term survival after chronic subdural haematoma[J]. J Clin Neurosci, 2016, 34: 100-104.
|
[7] |
Miah IP, Holl DC, Peul WC, et al. Dexamethasone therapy versus surgery for chronic subdural haematoma (DECSA trial): study protocol for a randomised controlled trial[J]. Trials, 2018, 19(1): 575.
|
[8] |
Qian Z, Yang D, Sun F, et al. Risk factors for recurrence of chronic subdural hematoma after burr hole surgery: potential protective role of dexamethasone[J]. Br J Neurosurg, 2017, 31(1): 84-88.
|
[9] |
Chen FM, Wang K, Xu KL, et al. Predictors of acute intracranial hemorrhage and recurrence of chronic subdural hematoma following burr hole drainage[J]. BMC Neurol, 2020, 20(1): 92.
|
[10] |
张毅,严红燕,彭强,等. 慢性硬膜下血肿复发的影像学因素分析[J]. 中华神经创伤外科电子杂志, 2019, 5(6): 345-348.
|
[11] |
Hori YS, Ebisudani Y, Aoi M, et al. Elevated serum fibrinogen degradation products on admission is a novel predictive factor for recurrence of chronic subdural hematoma[J]. World Neurosurg, 2018, 118: e753-e757.
|
[12] |
Zhang Y, Chen S, Xiao Y, et al. Effects of dexamethasone in the treatment of recurrent chronic subdural hematoma[J]. World Neurosurg, 2017, 105: 115-121.
|
[13] |
彭汤明,陈义天,刘亮,等. 慢性硬膜下血肿钻孔引流术后复发的危险因素的累积影响[J]. 中华神经医学杂志, 2017, 16(4): 412-415.
|
[14] |
Stavrinou P, Katsigiannis S, Lee JH, et al. Risk factors for chronic subdural hematoma recurrence identified using quantitative computed tomography analysis of hematoma volume and density[J]. World Neurosurg, 2017, 99: 465-470.
|
[15] |
Staniśić M, Hald J, Rasmussen IA, et al. Volume and densities of chronic subdural haematoma obtained from CT imaging as predictors of postoperative recurrence: a prospective study of 107 operated patients[J]. Acta Neurochir (Wien), 2013, 155(2): 323-333; discussion 333.
|
[16] |
Lutz K, Kamenova M, Schaedelin S, et al. Time to and possible risk factors for recurrence after burr-hole drainage of chronic subdural hematoma: a subanalysis of the cSDH-drain randomized controlled trial[J]. World Neurosurg, 2019, 132: e283-e289.
|
[17] |
Yang AI, Balser DS, Mikheev A, et al. Cerebral atrophy is associated with development of chronic subdural haematoma[J]. Brain Inj, 2012, 26(13-14): 1731-1736.
|
[18] |
叶晖,柳再明,周龙,等. 硬膜下积液演变成慢性硬膜下血肿的相关危险因素分析[J]. 卒中与神经疾病, 2018, 25(2): 213-214.
|
[19] |
王如海,孙菲琳,杨震,等. 硬膜下积液厚度对创伤性硬膜下积液转化为慢性硬膜下血肿的预测价值[J]. 中华脑科疾病与康复杂志(电子版), 2021, 11(4): 227-231.
|
[20] |
Wang D, Gao C, Xu X, et al. Treatment of chronic subdural hematoma with atorvastatin combined with low-dose dexamethasone: phase II randomized proof-of-concept clinical trial[J]. J Neurosurg, 2021, 134: 235-243.
|
[21] |
Jeong SI, Kim SO, Won YS, et al. Clinical analysis of risk factors for recurrence in patients with chronic subdural hematoma undergoing burr hole trephination[J]. Korean J Neurotrauma, 2014, 10(1): 15-21.
|